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INTRODUCTION
Between 30% and 50% of patients with epilepsy either fail to respond adequately to, or are unable to fully comply with, standard antiepileptic therapy 1, 2 . Approximately one-third of patients treated with currently available antiepileptic drugs have seizures that are refractory to therapy 3 . In addition, adverse effects prevent adequate seizure control in a reported 20-30% of patients taking antiepileptic drugs 4 . Individualized upward dose titration to an effective dose is one method employed to avoid unnecessary dose-related adverse effects 5 . Currently, antiepileptic drug development is focused on providing an agent with a broad spectrum of antiepileptic activity and with an overall improved safety, tolerability, and efficacy profile to maximize seizure control.
Levetiracetam, an S-enantiomer derivative of pyrrolidine acetamide, is a novel agent with a broadspectrum effect in animal models of partial and generalized epilepsy [6] [7] [8] . Levetiracetam has both antiepileptic and antiepileptogenic properties 6, 8, 9 . Although the mechanism of action of levetiracetam has not been fully elucidated, the drug does not appear to act at any recognized site of antiepileptic drug activity. Instead, in vitro studies suggest a brain-specific binding site 10 .
Compared with other antiepileptic drugs, levetiracetam has a wide margin of safety. Results of pre-clinical studies show no evidence for carcinogenic, mutagenic, or teratogenic potential 7 . Leve-tiracetam has a favourable pharmacokinetic profile in humans. Following oral administration, levetiracetam undergoes rapid and almost complete absorption; steady-state plasma levels are attained approximately 48 hours after administration. Levetiracetam exhibits linear kinetics, is minimally protein bound, and has no effect on hepatic cytochrome P450 enzymes. It is partly metabolized in blood and fully excreted in urine, mostly as unchanged drug 11 .
The clinical effects of levetiracetam have been evaluated in three placebo-controlled clinical studies of patients with epilepsy. In these studies, levetiracetam, initiated at 1000 mg daily and then increased up to 2000 mg or 3000 mg daily in 1000 mg increments, effectively reduced the frequency of seizures in patients with partial seizures 12 . It was well-tolerated, and the most commonly reported adverse events, reported for more than 3% of patients and with a difference of more than 3% between levetiracetam and placebo, were somnolence, asthenia, and dizziness (<15% of patients). Single-blind and open-label studies have shown encouraging results when levetiracetam is titrated upward to 4000 mg daily 13 . The purpose of the present study was to ascertain the tolerability and efficacy of levetiracetam at doses of 2000 mg and 4000 mg daily as add-on therapy in patients with refractory epilepsy, administered without titration. 14 . Patients had to have been maintained on a stable dosage regimen of up to three antiepileptic drugs for at least 3 months prior to study entry. In addition, they were required to have experienced at least four seizures in the 24 weeks prior to study entry. Women of childbearing potential were eligible only if they were using a reliable method of contraception. All patients provided written informed consent prior to enrolment, and the study was approved by the individual ethical review procedures of the participating centres.
PATIENTS AND METHODS

Study population
Patients were excluded if they had a history of allergy, alcohol or drug abuse, a serious medical condition that could interfere with the assessment of safety and efficacy, psychotic conditions, problems with absorption, metabolism, or elimination of drugs, including gastrointestinal dysfunction, or renal or hepatic insufficiency.
Study design
This was a multicentre, double-blind, randomized study with three parallel groups designed to evaluate the tolerability and efficacy of two oral doses of levetiracetam (2000 mg and 4000 mg daily) as addon therapy in patients with refractory epilepsy of any type. The study was conducted at 37 sites in Belgium and the United Kingdom between September 1993 and March 1997. The study consisted of four phases: a 1-to 4-week baseline period, a 24-week double-blind treatment period, a 24-week open-label treatment period, and a 4-week run-out/downtitration period (or entry into an open follow-up study) (Fig. 1 ).
Patients were seen at an initial screening visit, and if eligible, were randomized within 4 weeks (baseline) to 2000 mg daily (1000 mg twice daily) or 4000 mg daily (2000 mg twice daily) of levetiracetam, or matching placebo tablets for 24 weeks. Randomization occurred in blocks of three, defining the treatment numbers per investigator. In each block, a random procedure (generated by the RANUNI function of SAS software) performed the permutation of the three treatment numbers. Patients in each study centre were assigned treatment numbers according to the number of the country/principal investigator and the chronological order of their entry into the study. Levetiracetam was provided as white 500 mg tablets and placebo as matching tablets, equal in appearance and taste. Both levetiracetam and placebo were supplied by UCB S.A. Pharma Sector.
The assigned dose was initiated at the start of active treatment. Visits were scheduled after 4, 12, and 24 weeks of double-blind treatment. At the end of this period, seizure-free patients continued on their assigned dose of levetiracetam for an additional 24 weeks in the open-label treatment period with visits after 12 and 24 weeks. All patients who were not seizure free at the end of the double-blind treatment period received 4000 mg daily of levetiracetam (without uptitration) in an open-label fashion. At the final visit of the study, levetiracetam was discontinued abruptly (run-out) or decreased by 1000 mg per week, or patients entered an open follow-up study. The investigator could withdraw patients from the study if consent was withdrawn, the double-blind code was broken, if an adverse event occurred that was considered by the investigator to require discontinuation, or if the patient became pregnant. nations, haematological and blood chemistry parameters, urinalyses, and antiepileptic drug plasma levels were carried out at each study visit. Adverse events were recorded in detail and rated by investigators as mild, moderate, or severe. A causal relationship to study treatment was assessed by investigators as highly probable, probable, possible, unlikely, or no relationship.
Measurement of efficacy.
Throughout the study, all patients completed daily record cards on which they logged the number, duration, description, and date of each seizure. At each visit, the investigator recorded the number of seizures and classified each seizure according to ILAE criteria. The main efficacy assessment was the responder rate, defined as the proportion of patients achieving a ≥50% reduction in total seizure frequency after having completed 24 weeks of doubleblind treatment compared with baseline. Other efficacy variables included responder rates after 4 weeks of double-blind treatment, and seizure frequency by seizure type and number of seizure-free patients.
Statistical methods
The intention-to-treat population included all randomized patients who had received at least one dose of study medication. The inferential intention-to-treat population consisted of the set of patients from the intention-to-treat population who provided data for the relevant treatment period(s). All treatment comparisons were made using two-tailed tests at the 0.05 significance level. The responder rate analyses were performed by means of logistic regression. Odds ratios for obtaining a 50% seizure reduction and 95% confidence interval were calculated. Median percentage reduction of weekly seizure frequency per seizure type (I and II) were analysed using the Wilcoxon rank sum test.
Adverse events were tabulated by body system, preferred COSTART term, severity, and relationship to the study drug. The numbers of patients who experienced at least one adverse event were compared using logistic regression. Baseline and study results of laboratory tests, vital signs, and mean trough antiepileptic drug plasma levels were compared among treatment groups using the Kruskal-Wallis test on difference from baseline.
RESULTS
Patient demographics
A total of 136 patients were screened; 119 patients were randomized to double-blind treatment and comprised the intention-to-treat population: 39 in the placebo group, 42 in the group receiving levetiracetam 2000 mg daily, and 38 in the group receiving levetiracetam 4000 mg daily (Fig. 2) . Treatment groups were comparable with respect to baseline characteristics (Table 1) . Across all treatment groups, the mean age was 38 years, the duration of epilepsy ranged from 0.4 to 57.6 years, and the mean age of epilepsy onset was 14.4 years. Median seizure frequency was determined for the set of patients from the intention-totreat population who had adequate data (non-missing and properly completed) at both baseline and following randomization. At baseline, it was 1.24 (N = 36), groups, respectively. Sixteen patients were completely seizure free during the baseline period, and in the efficacy analysis, these patients were treated as nonresponders. The most common antiepileptic drug regimens at baseline included carbamazepine (N = 69), valproate (N = 38), phenytoin (N = 37), or phenobarbitone (N = 25).
Patient disposition
Among the 119 patients randomized to drug treatment, 33 (placebo, N = 10; levetiracetam 2000 mg daily, N = 14; levetiracetam 4000 mg daily, N = 9) discontinued during the double-blind treatment period (Fig. 2) . The number of patients who discontinued was comparable among treatment groups. Most patients who discontinued in the first month did so because of adverse events (Fig. 3) . Somnolence was the most commonly reported reason for study discontinuation. A total of 86 patients continued into the open-label treatment period (Table 2 ).
Safety and tolerability
The incidence of adverse events was similar among study groups (placebo, 84.6%, 33/39; levetiracetam 2000 mg daily, 83.3%, 35/42; levetiracetam 4000 mg daily, 84.2%, 32/38). In the double-blind treatment period, the most frequently reported adverse events were somnolence and asthenia (COSTART term for fatigue or tiredness) ( Table 3 ). The incidence of somnolence was highest in patients receiving 4000 mg daily of levetiracetam (44.7%, 17/38), but was comparable between the 2000 mg daily treatment group and placebo (26.2%, 11/42 and 25.6%, 10/39, respectively). Asthenia was most commonly reported by patients in the 2000 mg daily treatment group (31.0%, 13/42), but was similar between the 4000 mg daily treatment group and placebo group (13.2%, 5/38 and 15.4%, 6/39, respectively). Other frequently reported adverse events (≥10% incidence in at least one of the levetiracetam treatment groups) were accidental injury (more frequent in the placebo group), infection, nausea, dizziness, and urinary tract infection. Adverse events generally appeared within the first month There were no significant changes in clinical laboratory parameters nor in any physical or neurological examination among the three treatment groups throughout the study. No changes were observed in concomitant antiepileptic trough drug concentrations.
Efficacy
Double-blind treatment period. A total of 86 patients completed 24 weeks of double-blind treatment and had adequate seizure data at both baseline and week 24 for efficacy assessment. After 24 weeks of treatment, the responder rate of the inferential intention-totreat population (N = 86) was 48.1% (13/27) and 28.6% (8/28) in patients treated with levetiracetam 2000 mg and 4000 mg daily, respectively, compared with placebo (16.1%, 5/31) (Fig. 4) . The difference in response was statistically significant between the 2000 mg daily treatment group and placebo (P = 0.01). After 24 weeks, the odds of obtaining a reduction in seizure frequency of ≥50% with levetiracetam 2000 mg and 4000 mg daily were 4.9 (95% confidence interval [CI]: 1.4; 16.8) and 2.0 (95% CI:0.6; 7.2) higher than the odds of obtaining the same response with placebo, respectively. Responder rates after 4 weeks of double-blind treatment were consistent with the 24-week findings. Differences in responder rates were statistically significant between the levetiracetam 2000 mg daily treatment group and placebo, 44.1% vs. 19.4%, respectively, (P < 0.05). The responder rate in patients who received 4000 mg daily of levetiracetam was 33.3%.
For all seizure types, an overall reduction in median seizure frequency was observed for the levetiracetam treatment groups compared with baseline. Median seizure frequency was 0.62 and 0.59 per week with levetiracetam 2000 mg and 4000 mg daily, respectively (1.21 and 1.34 at baseline, respectively). In contrast, median seizure frequency increased for patients who received placebo (1.40 vs. 1.24 at baseline). In the levetiracetam treatment groups, the median percentage reductions in seizure frequency were similar between seizure types I and II, and were higher when compared with placebo, although differences were not significant (Fig. 5) . Throughout the entire double-blind treatment period, seven patients were completely seizure free; of these, four patients had received 2000 mg daily, two received 4000 mg daily of levetiracetam, and one received placebo.
Open-label treatment period
In the open-label treatment period, all treatment groups received 4000 mg daily of levetiracetam, except for five patients (placebo, N = 1; levetiracetam 2000 mg daily, N = 4) who continued with their double-blind treatment because they were seizure free throughout the doubleblind period. Overall, according to analysis using the last available observation under treatment, 43% of the 79 patients had a ≥50% reduction in seizure frequency following open-label treatment compared with baseline. The percentage of responders was 44.0% in patients initially treated with placebo, 46.2% in patients initially treated with levetiracetam 2000 mg daily, and 39.3% in patients initially treated with levetiracetam 4000 mg daily (Fig. 4) . Importantly, an increase in response was observed in patients who had received placebo in the double-blind treatment period but were subsequently switched to treatment with 4000 mg daily of levetiracetam in the open-label treatment period (response rose from 16.7% to 44.0% [11/25] , respectively). The responder rate of patients switched from 2000 mg to 4000 mg daily of levetiracetam was similar (46%; 12/26).
DISCUSSION
Results of this placebo-controlled study demonstrate that levetiracetam was well tolerated at doses of 2000 mg and 4000 mg daily without titration in patients with refractory epilepsy. The most frequent adverse effects were somnolence and asthenia. Somnolence was most often cited as the reason for study discontinuation. In this study, the occurrence of somnolence was more pronounced at the initiation of treatment with levetiracetam and with the higher dose. This study supports pre-clinical findings [6] [7] [8] by demonstrating that levetiracetam could have a broad-spectrum potential because it decreased the frequency of partial and secondarily and primary generalized seizures. Specific studies in generalized seizures are ongoing. A clinical response was achieved early in the course of treatment. Responder rates after 4 and 24 weeks were similar. Throughout the double-blind treatment period, four patients receiving levetiracetam 2000 mg daily and two receiving 4000 mg daily of levetiracetam remained seizure free compared with the one receiving placebo.
Levetiracetam has been evaluated in three other larger clinical trials at doses ranging from 1000 mg to 3000 mg daily 12 . Based on pooled efficacy data, at all doses tested (1000 mg, 2000 mg, and 3000 mg daily) levetiracetam was more effective than placebo in reducing the weekly partial seizure frequency 12 . A distinct dose-response relationship was observed, with responder rates of 27.7%, 31.6%, and 41.3% for the 1000 mg, 2000 mg, and 3000 mg daily doses, respectively. In the present study, efficacy was higher with levetiracetam 2000 mg daily than 4000 mg daily, with responder rates of 48.1% and 28.6%. When patients receiving 2000 mg daily were switched to the higher 4000 mg daily dose in the open-label period, no additional efficacy was gained and the incidence of somnolence was higher at the higher dose. Based on these results, levetiracetam may have a therapeutic window with optimal response achieved at 3000 mg daily. However, the present study was not powered to detect a significant difference between the levetiracetam treatment arms. The study population was small and there was an overall low baseline seizure frequency. In addition, the study consisted of a short 4-week baseline period. Results should therefore be interpreted with care, and no firm conclusions can be made about efficacy.
CONCLUSIONS
Levetiracetam can be safely initiated at high therapeutic doses from 2000-4000 mg daily and has broadspectrum potential. The higher dose may be used, possibly at the expense of an increased incidence of somnolence, but it is not necessarily more effective than the lower one, suggesting a therapeutic window of efficacy. Seizure control is rapidly achieved without the need for titration. Although not likely to be the general recommendation for use, this represents an advantage over other antiepileptic drugs in terms of ease of use in clinical practice.
